Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 514

1.

Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.

Waters LJ, Moyle G, Bonora S, D'Avolio A, Else L, Mandalia S, Pozniak A, Nelson M, Gazzard B, Back D, Boffito M.

Antivir Ther. 2007;12(5):825-30.

PMID:
17713166
2.

Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.

Di Giambenedetto S, De Luca A, Villani P, Bacarelli A, Ragazzoni E, Regazzi M, Cauda R, Navarra P.

HIV Med. 2008 Apr;9(4):239-45. doi: 10.1111/j.1468-1293.2008.00555.x.

3.

Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.

von Hentig N, Dauer B, Haberl A, Klauke S, Lutz T, Staszewski S, Harder S.

Eur J Clin Pharmacol. 2007 Oct;63(10):935-40. Epub 2007 Jul 31.

PMID:
17665183
4.

Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.

Boffito M, Else L, Back D, Taylor J, Khoo S, Sousa M, Pozniak A, Gazzard B, Moyle G.

Antivir Ther. 2008;13(7):901-7.

PMID:
19043924
5.

Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.

Pruvost A, Negredo E, Théodoro F, Puig J, Levi M, Ayen R, Grassi J, Clotet B.

Antimicrob Agents Chemother. 2009 May;53(5):1937-43. doi: 10.1128/AAC.01064-08. Epub 2009 Mar 9.

6.

Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.

Pham PA, Flexner C, Parsons T, Vasist L, Fuchs E, Carson K, Agarwala S, Barditch-Crovo P.

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):201-5.

PMID:
17414932
7.

Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.

Klein CE, Chiu YL, Cai Y, Beck K, King KR, Causemaker SJ, Doan T, Esslinger HU, Podsadecki TJ, Hanna GJ.

J Clin Pharmacol. 2008 May;48(5):553-62. doi: 10.1177/0091270007313392.

PMID:
18440920
8.

The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.

von Hentig N, Babacan E, Lennemann T, Knecht G, Carlebach A, Harder S, Staszewski S, Haberl A.

J Antimicrob Chemother. 2008 Sep;62(3):579-82. doi: 10.1093/jac/dkn204. Epub 2008 May 13.

PMID:
18477709
9.

Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.

Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL; Adolescent Trials Network for HIV/AIDS Interventions.

Antimicrob Agents Chemother. 2008 Feb;52(2):631-7. Epub 2007 Nov 19.

10.

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.

Le Tiec C, Barrail A, Goujard C, Taburet AM.

Clin Pharmacokinet. 2005;44(10):1035-50. Review.

PMID:
16176117
11.

Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.

Soriano V, García-Gasco P, Vispo E, Ruiz-Sancho A, Blanco F, Martín-Carbonero L, Rodríguez-Novoa S, Morello J, de Mendoza C, Rivas P, Barreiro P, González-Lahoz J.

J Antimicrob Chemother. 2008 Jan;61(1):200-5. Epub 2007 Nov 13.

PMID:
17999977
12.

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.

Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, Rezk NL, Bridges AS, Stewart PW, Cohen MS, Kashuba AD.

AIDS. 2007 Sep 12;21(14):1899-907.

13.

Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.

van Luin M, Van der Ende ME, Richter C, Visser M, Faraj D, Van der Ven A, Gelinck L, Kroon F, Wit FW, Van Schaik RH, Kuks PF, Burger DM.

AIDS. 2010 May 15;24(8):1223-6. doi: 10.1097/QAD.0b013e3283389129.

PMID:
20299957
14.

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.

Cohen C, Nieto-Cisneros L, Zala C, Fessel WJ, Gonzalez-Garcia J, Gladysz A, McGovern R, Adler E, McLaren C; BMS AI424-043 Study Group.

Curr Med Res Opin. 2005 Oct;21(10):1683-92.

PMID:
16238909
15.

Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting.

Haberl A, Moesch M, Nisius G, Stephan C, Bickel M, Khaykin P, Kurowski M, Brodt R, von Hentig N.

Eur J Clin Pharmacol. 2010 Apr;66(4):375-81. doi: 10.1007/s00228-009-0767-8. Epub 2009 Dec 24.

PMID:
20033681
16.

Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.

Colombo S, Buclin T, Franc C, Guignard N, Khonkarly M, Tarr PE, Rochat B, Biollaz J, Telenti A, Decosterd LA, Cavassini M.

Antivir Ther. 2006;11(1):53-62.

PMID:
16518960
17.

Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.

Boffito M, Maitland D, Dickinson L, Back D, Hill A, Fletcher C, Moyle G, Nelson M, Gazzard B, Pozniak A.

AIDS Res Hum Retroviruses. 2006 Aug;22(8):749-56.

PMID:
16910830
18.

Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.

Ofotokun I, Chuck SK, Binongo JN, Palau M, Lennox JL, Acosta EP.

J Clin Pharmacol. 2007 Aug;47(8):970-7. Epub 2007 Jul 5.

19.

Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.

la Porte C, van Heeswijk R, Mitchell CD, Zhang G, Parker J, Rongkavilit C.

Antivir Ther. 2009;14(4):603-6.

PMID:
19578247
20.

Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen.

von Hentig N, Kaykhin P, Stephan C, Babacan E, Stürmer M, Staszewski S, Lötsch J.

Antimicrob Agents Chemother. 2008 Jun;52(6):2273-5. doi: 10.1128/AAC.01565-07. Epub 2008 Apr 14.

Supplemental Content

Support Center